New Products, Protocols

OptiNose files for $100M IPO; GSK wins three-in-one COPD OK

⇨ Yardley, PA-based OptiNose is joining the growing line for Nasdaq, filing for a $100 million IPO, according to the S-1. The filing came right on the heels of an OK for XHANCE — previously referred to by the development name OPN-375 — for the treatment of nasal polyps.

GSK got some good news today, winning FDA approval of the first three-in-one once-daily therapy for COPD. The move comes after the EMA endorsed the inhaler last week.

⇨ After nearly a decade spent collaborating with Celgene, Acceleron $XLRN says it has gained rights to develop sotatercept for pulmonary arterial hypertension, with plans to launch a Phase II study during the first half of next year.

⇨ The microcap biotech Juniper Pharmaceuticals $JNP is refocusing and reorganizing. The plan is to slash the staff roster by 8% and concentrate on “the core businesses of Crinone progesterone gel and Juniper Pharma Services” at the Boston-based women’s healthcare company.

Nabriva Therapeutics $NBRV is following up on a positive Phase III study for its antibiotic with an $80 million stock offering.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->